Evidence map›Paper›PMID 35838957›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2022

SARS-CoV-2 Host Immunogenetic Biomarkers.

Maemu P Gededzha, Nakampe Mampeule, Anastasia Gandini, Elizabeth S Mayne

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Maemu P GededzhaDepartment of Immunology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Maemu.gededzha@nhls.ac.za.
Nakampe MampeuleDepartment of Immunology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Anastasia GandiniDepartment of Immunology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Elizabeth S MayneDepartment of Immunology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Funding

Human Heredity and Health in Africa Consortium BiorepositoryU24HG007438 · NHGRI · WITS HEALTH CONSORTIUM (PTY), LTD · PI MAYNE, ELIZABETH · 2019 to 2022
$1.3M
NHGRI NIH HHS U24 HG007438
6 · The paper itself

Abstract

SARS-CoV-2 causes generally mild symptoms, with approximately 10-20% of cases progressing to severe disease. The pathophysiologic mechanisms by which SARS-CoV-2 causes severe disease are largely unknown. Data have indicated the involvement of different immunogenetic markers such as HLA, T, and B cells, to be associated with disease outcome. This has led to interest in these genes as potential biomarkers of SARS-CoV-2 susceptibility and for predicting prognosis and response to vaccines and other therapeutic strategies. In this chapter, we discussed outline protocols for characterizing these potential biomarkers and methods for identifying SARS-CoV-2 biomarkers using the Luminex

Indexed as

COVID-19SARS-CoV-2BiomarkersHigh-Throughput Nucleotide SequencingHumansImmunogeneticsBiomarkersB cellHLAImmunogenetic markerLuminexNext-generation sequencingNGSSARS-COV-2T cell

Identifiers

PMID35838957

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.